

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**AU STAR**

**奥 星**

**Austar Lifesciences Limited**

**奥星生命科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6118)**

## **CHANGE OF EXECUTIVE DIRECTORS AND CHANGE OF COMPOSITION OF BOARD COMMITTEE**

### **RESIGNATION OF EXECUTIVE DIRECTOR**

The board (“**Board**”) of directors (“**Directors**”, each, a “**Director**”) of Austar Lifesciences Limited (“**Company**”, together with its subsidiaries, the “**Group**”) announces that due to other work commitment, Mr. Chen Yuewu (“**Mr. Chen**”) resigned as an executive Director and ceased to act as a member of the risk management committee of the Board (“**Risk Management Committee**”) with effect from 26 August 2025 (“**Effective Date**”).

Mr. Chen has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company (“**Shareholders**”).

The Board would like to sincerely thank and express its appreciation to Mr. Chen for his valuable contribution to the Group during his tenure in the Company.

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board further announces that with effect from the Effective Date, Mr. Bian Ce (“**Mr. Bian**”) has been appointed as an executive Director and a member of the Risk Management Committee in place of Mr. Chen.

The biographical details of Mr. Bian are set out below:

Mr. Bian Ce, aged 49, graduated from Beijing University of Technology in 1998 with a bachelor's degree in engineering, specialising in refrigeration equipment and cryogenic technology. With over 20 years of experience in the field of core process equipment for injectable drugs, Mr. Bian has gained extensive experience and achieved outstanding results in various aspects relating to core process equipment for injectable drugs, such as in terms of research and development, manufacturing, international market expansion and business development, as well as industry mergers, acquisitions, and integration.

Prior to joining the Group, Mr. Bian held senior roles at major pharmaceutical equipment manufacturers, including IMA Life (Beijing) Pharmaceutical Systems Co., Ltd. ("**IMA Life**") and Truking Technology Limited (whose shares are listed on the Shenzhen Stock Exchange (Stock Code: 300358)), where he was primarily responsible for technical research and development and international market development.

In April 2022, Mr. Bian joined the Group as the vice president and simultaneously served as the general manager of a subsidiary of the Company. In January 2024, he was promoted to senior vice president of the Group, mainly responsible for overseeing the Integrated Process and Packaging Systems ("**IPS**") Business Group and managing the Group's International Business Division. Mr. Bian is also a director of a number of subsidiaries of the Company.

Mr. Bian was named as a defendant in a civil proceeding initiated by IMA Life concerning alleged misappropriation of trade secrets. IMA Life alleged that Mr. Bian and two of his former colleagues (collectively, the "**Defendants**") improperly disclosed confidential technical information of IMA Life during and post-employment. In December 2013, the Beijing Chaoyang District People's Court ruled against the Defendants, finding they had engaged in unauthorised disclosure of proprietary technical documents of IMA Life through electronic communications. This constituted a breach of confidentiality obligations and unfair competition under the laws of the People's Republic of China. The court ordered the Defendants to cease the infringing conduct and jointly pay RMB300,000 in compensation for IMA Life's damages and RMB150,000 in legal costs. Mr. Bian confirmed that he had fully complied with the court's orders, with no subsequent violations over the past decade. The Board considers that this historical matter does not affect Mr. Bian's fitness to serve as an executive Director, given his clean compliance record since joining the Group, strong leadership in growing the Group's IPS Business Group and his proven adherence to the Group's ethical standards.

Pursuant to the appointment letter entered into between the Company and Mr. Bian, Mr. Bian was appointed as an executive Director for a term of two years commencing on the Effective Date, subject to certain early termination clauses in the appointment letter. He is subject to re-election at the first annual general meeting of the Company after his appointment and thereafter subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. Mr. Bian is not entitled to additional remuneration for serving as an executive

Director beyond the remuneration payable under his existing employment contract with the Group. Under his existing employment contract, Mr. Bian is entitled to an annual salary of RMB948,000, plus a discretionary bonus determined with reference to his duties, responsibilities and the Group's performance.

Save as disclosed herein, as at the date of this announcement, Mr. Bian (i) has not held any directorships in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any other major appointments and professional qualifications; (iii) does not hold any other position with the Company or other members of the Group; and (iv) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (as respectively defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**")) of the Company.

As at the date of this announcement, Mr. Bian is not interested or deemed to be interested in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Mr. Bian confirms that there is no other information which is discloseable pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and that there are no other matters relating to his appointment that need to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to welcome Mr. Bian for joining the Board.

By Order of the Board  
**Austar Lifesciences Limited**  
**Ho Kwok Keung, Mars**  
*Chairman and Chief Executive Officer*

Hong Kong, 26 August 2025

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Madam Zhou Ning and Mr. Bian Ce; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.*